Literature DB >> 23825102

Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation.

Frank Cortazar1, Roque Diaz-Wong, David Roth, Tamara Isakova.   

Abstract

Chronic kidney disease is a major public health problem that is associated with increased risks of kidney disease progression, cardiovascular disease and death. Kidney transplantation remains the renal replacement therapy of choice for patients with end-stage kidney disease. Despite impressive strides in short-term allograft survival, there has been little improvement in long-term kidney graft survival, and rates of death with a functioning allograft remain high. Long-term safety profiles of existing immunosuppressive regimens point to a need for continued search for alternative agents. This overview discusses emerging evidence on a few promising therapeutic approaches, juxtaposes conflicting findings and highlights remaining knowledge gaps.

Entities:  

Keywords:  belatacept; corticosteroids; mammalian target of rapamycin inhibitors

Mesh:

Substances:

Year:  2013        PMID: 23825102      PMCID: PMC3811055          DOI: 10.1093/ndt/gft231

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  34 in total

1.  Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.

Authors:  J O Medina Pestana; J M Grinyo; Y Vanrenterghem; T Becker; J M Campistol; S Florman; V D Garcia; N Kamar; P Lang; R C Manfro; P Massari; M D C Rial; M A Schnitzler; S Vitko; T Duan; A Block; M B Harler; A Durrbach
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

2.  Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group.

Authors:  N Ahsan; D Hricik; A Matas; S Rose; S Tomlanovich; A Wilkinson; M Ewell; M McIntosh; D Stablein; E Hodge
Journal:  Transplantation       Date:  1999-12-27       Impact factor: 4.939

3.  Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.

Authors:  F Cortazar; M Z Molnar; T Isakova; M E Czira; C P Kovesdy; D Roth; I Mucsi; M Wolf
Journal:  Am J Transplant       Date:  2011-11-04       Impact factor: 8.086

4.  Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.

Authors:  T Isakova; H Xie; S Messinger; F Cortazar; J J Scialla; G Guerra; G Contreras; D Roth; G W Burke; M Z Molnar; I Mucsi; M Wolf
Journal:  Am J Transplant       Date:  2012-10-01       Impact factor: 8.086

5.  OPTN/SRTR 2011 Annual Data Report: kidney.

Authors:  A J Matas; J M Smith; M A Skeans; K E Lamb; S K Gustafson; C J Samana; D E Stewart; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2013-01       Impact factor: 8.086

6.  Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

Authors:  H Kreis; J M Cisterne; W Land; L Wramner; J P Squifflet; D Abramowicz; J M Campistol; J M Morales; J M Grinyo; G Mourad; F C Berthoux; C Brattström; Y Lebranchu; P Vialtel
Journal:  Transplantation       Date:  2000-04-15       Impact factor: 4.939

Review 7.  T-cell regulation by CD28 and CTLA-4.

Authors:  M L Alegre; K A Frauwirth; C B Thompson
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

8.  Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

Authors:  F Vincenti; C P Larsen; J Alberu; B Bresnahan; V D Garcia; J Kothari; P Lang; E Mancilla Urrea; P Massari; G Mondragon-Ramirez; R Reyes-Acevedo; K Rice; L Rostaing; S Steinberg; J Xing; M Agarwal; M B Harler; B Charpentier
Journal:  Am J Transplant       Date:  2011-10-12       Impact factor: 8.086

9.  Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up.

Authors:  M M Sarwal; R B Ettenger; V Dharnidharka; M Benfield; R Mathias; A Portale; R McDonald; W Harmon; D Kershaw; V M Vehaskari; E Kamil; H J Baluarte; B Warady; L Tang; J Liu; L Li; M Naesens; T Sigdel; Janie Waskerwitz; O Salvatierra
Journal:  Am J Transplant       Date:  2012-06-13       Impact factor: 8.086

10.  Sirolimus and secondary skin-cancer prevention in kidney transplantation.

Authors:  Sylvie Euvrard; Emmanuel Morelon; Lionel Rostaing; Eric Goffin; Anabelle Brocard; Isabelle Tromme; Nilufer Broeders; Veronique del Marmol; Valérie Chatelet; Anne Dompmartin; Michèle Kessler; Andreas L Serra; Günther F L Hofbauer; Claire Pouteil-Noble; Josep M Campistol; Jean Kanitakis; Adeline S Roux; Evelyne Decullier; Jacques Dantal
Journal:  N Engl J Med       Date:  2012-07-26       Impact factor: 91.245

View more
  1 in total

Review 1.  Effectiveness and safety of calcineurin inhibitor withdrawal in kidney transplantation: a meta-analysis of randomized controlled trials.

Authors:  Hongwei Bai; Yeyong Qian; Bingyi Shi; Zhen Wang; Gang Li; Yu Fan; Ming Yuan; Lupeng Liu
Journal:  Clin Exp Nephrol       Date:  2015-03-29       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.